---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042202"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:20:23.962539+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health gets $10M ARPA-H award for endometriosis blood test

## Summary
- Selected by ARPA-H for $10 million in milestone-based funding over two years to develop EndoMDx blood test for endometriosis.
- EndoMDx is a multi-marker miRNA blood test intended to aid in detection, currently requiring laparoscopic surgery for diagnosis.
- Over 1,700 submissions vied for funding; Aspira will collaborate with ARPA-H Program Manager and Investor Catalyst Hub.
- Virtual Investor Day scheduled for October 29, 2024, at 3:00 pm ET to discuss ARPA-H award and pipeline update.

## SEC filing metadata
- accession: 0001493152-24-042202
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000149315224042202/0001493152-24-042202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000149315224042202/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042202
- JSON: https://secwatch.observer/filing/0001493152-24-042202.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.